In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Galectin-3 as a risk factor recurrence of atrial fibrillation in patients with metabolic syndrome

Session Poster session 1

Speaker Assistant Professor Valery Ionin

Event : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Rhythm Control, Antiarrhythmic Drugs
  • Session type : Poster Session

Authors : VA Ionin (Saint-Petersburg,RU), EL Zaslavskaya (Saint-Petersburg,RU), DS Skuridin (Saint-Petersburg,RU), EU Petrisheva (Saint-Petersburg,RU), AG Filatova (Saint-Petersburg,RU), EI Baranova (Saint-Petersburg,RU), EV Shlyakhto (Saint-Petersburg,RU)

VA Ionin1 , EL Zaslavskaya2 , DS Skuridin2 , EU Petrisheva2 , AG Filatova2 , EI Baranova2 , EV Shlyakhto1 , 1Almazov National Medical Research Centre - Saint-Petersburg - Russian Federation , 2Pavlov First Saint-Petersburg State Medical University - Saint-Petersburg - Russian Federation ,


Background: Galectin-3 (Gal-3) – biomarker of fibrosis is increased in patients with atrial fibrillation (AFib) and metabolic syndrome (MetS). We propose that Gal-3 can impact on progression of the arrhythmia. Objective of the study was to evaluate the role of Gal-3 in predicting the effect of antiarrhythmic drug therapy in patients with AFib and MetS. 

Methods: 764 AFib patients hospitalized in cardiology department (2016-2017 years) were examined. 180 patients with MetS (IDF, 2005) and paroxysmal (n=100) or persistent (n=80) AFib were included in prospective study. Groups did not differ significantly by gender, age, eGFR (p>0,05), volumes left and right atrium. The examination includes: medical history, anthropometry, echocardiography, serum Gal-3 (ELISA). Patients were taking antiarrhythmic drugs: amiodarone (32%), beta-blockers (42%), sotalol (12%), propafenone (14%) during 16,7±6,9 months. After that we analyzed the clinical data and the effectiveness of antiarrhythmic drug therapy, which is considered effective if there were no reported paroxysms of AFib during follow-up. 

Results: Gal-3 in patients with persistent AFib was higher than in patients with paroxysmal AFib (1,02 [0,52;3,14] and 0,54 [0,41;1,31] ng/ml, ?=0,03). In patients with 1-2 paroxysms in month Gal-3 was higher than in patients with 1-2 paroxysms in year (1,31 [0,92;4,21] and 0,53 [0,41;0,72] ng/ml, ?<0,001). Gal-3 in patients with recurrent paroxysms of AFib and without the effect of antiarrhythmic therapy was higher than in patients without recurrent paroxysms of AFib irrespective of antiarrhythmic drug (1,31 [0,75,2,49] and 0,50 [0,41;0,72] ng/ml, p<0,001). The multivariate regression analysis demonstrated that Gal-3 is an independent predictor of non-effective antiarrhythmic drug therapy of AFib (OR=2,38, 95% CI 1,12-5,04, p=0,024). In patients with AFib and MetS who had serum Gal-3 above 0,77 ng/ml (cut-off point on ROC-curve) the risk of non-effective antiarrhythmic therapy was in 3,6 fold higher during follow-up the study (RR=3,6, 95% CI 1,6-7,9, p=0,002). 

Conclusions: The level of serum galectin-3 in patients with persistent atrial fibrillation is higher than in patients with paroxysmal. Patients with higher level of galectin-3 have a higher risk of non-effective antiarrhythmic drug therapy, that may be an additional indication for surgical treatment.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are